# PLIMATH (NCT03331731)

> A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: Hodgkin lymphoma unsuitable for ABVD

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03331731
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Hodgkin Lymphoma
- Interventions: pembrolizumab
- Enrollment: 27
- Primary outcome: Response using Lugano Criteria

## Indexed commentary on PLIMATH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=plimath-nct03331731